Enhancing Patient Care in Oncology through Remote Patient Monitoring

By Staff Writer

August 22, 2024

Introduction

Optimising communication between patients and clinical teams is crucial in improving the quality of care and patient satisfaction, particularly following a cancer diagnosis. Patient-reported outcomes (PROs) have emerged as a key facilitator of this communication, revealing symptom patterns that clinicians might overlook. Remote patient monitoring (RPM), a digital innovation, enables patients to report PROs electronically (ePROs), allowing healthcare teams to monitor symptoms and intervene in real-time. A recent publication explored the real-world implementation of remote patient monitoring in oncology and RPM across 33 centres in Europe, focusing on its impact on patient engagement and symptom management.

Remote Patient Monitoring in Oncology

PROs provide a direct insight into the patient’s experience, particularly in terms of symptom incidence and trajectories. Studies have consistently shown that integrating PROs and ePROs into oncology care enhances communication, reduces symptom burden, improves quality of life, and boosts treatment adherence. The European Society of Medical Oncology (ESMO) has recognised these benefits, recommending the implementation of RPM systems that connect patients and healthcare teams with proactive alerts for severe symptoms.

Despite the proven advantages, the adoption of ePROs in routine clinical practice faces several challenges. These include provider resistance, data accuracy concerns, privacy issues, reimbursement hurdles, and technological illiteracy. The COVID-19 pandemic, however, accelerated the introduction of RPM systems in oncology due to the increased need for decentralised care. Large multicentric initiatives, especially in North America, have demonstrated RPM’s feasibility but highlighted the need for optimised clinical pathways and digital systems to achieve optimal participation and clinical impact.

Figure 1. Adherence to ePRO surveys.

Implementation of RPM Pathway in Europe

The study reports on the implementation of an RPM pathway across 33 centres in France and Belgium, enrolling 3015 patients from November 2021 to August 2023. The pathway demonstrated high patient engagement, with an average compliance rate of 82% for weekly ePROs. Nurse navigators responded to patients’ alerts within a median time of 13 hours and 41 minutes, leading to significant reductions in symptom severity.

Several factors contributed to the high level of patient engagement observed in this study. A structured and well-defined implementation process, adaptive to various barriers, played a crucial role. This process considered software functionality, measured outcomes, personnel deployment, leadership, culture, workflow, and patient engagement. The study also benefited from prior experiences and guidelines, such as the CAPRI trial and recommendations from the PROTEUS Consortium.

The RPM pathway was co-designed with input from healthcare professionals (HCPs), researchers, patients, and technology experts. Patient representatives were involved in all phases of development, ensuring that the technology met their needs. The RPM technology solution, Resilience PRO, included features that enhanced patient engagement and empowerment, such as a library of educational content personalised to the patient’s symptoms.

Challenges and Future Directions

Despite the success, challenges remain in implementing RPM in routine care. These include the need for organisational changes within cancer care centres, such as dedicated teams for RPM planning, deployment, patient onboarding, and alert management. The recent announcement by the French Ministry of Health to reimburse RPM for chronic conditions, including cancer, is expected to accelerate adoption by addressing financial and structural obstacles.

In the United States, the Centers for Medicare & Medicaid Services (CMS) has reimbursed remote therapeutic monitoring (RTM) since late 2022, following specific criteria. The inclusion of a chat functionality in the Resilience PRO platform in pilot centres since August 2023 aims to further improve alert management and reduce HCP burden.

Conclusion

The real-world implementation of an RPM pathway across 33 cancer centres in France and Belgium has proven feasible and effective, with high levels of patient and provider engagement. The RPM pathway facilitated significant improvements in symptom control, demonstrating its potential to enhance oncology care. Future studies will focus on evaluating the impact of educational content, optimising alert management, and assessing cost-effectiveness.

Reference url

Recent Posts

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.